⁠CJC-1295 With DAC (Long-Acting GHRH Analogue)⁠

CJC-1295 With DAC | Extended-Release GHRH Analogue

CJC-1295 With DAC is a modified synthetic 29-amino acid tetrasubstituted peptide analogue of growth hormone-releasing hormone, uniquely fused to a Drug Affinity Complex (DAC) via a reactive maleimide linker. While native GHRH and Modified GRF 1-29 are subject to rapid in vivo metabolic clearance, this formulation is engineered to undergo an instantaneous, non-reversible covalent bond with endogenous plasma proteins—specifically albumin—following application.

The presence of the DAC group shields the core peptide sequence from enzymatic breakdown by dipeptidyl peptidase-4 (DPP-4) and renal filtration. This architectural shift profoundly extends the compound’s experimental half-life to approximately 6 to 8 days. Consequently, it provides investigators with a specialized preclinical asset capable of sustaining continuous, baseline pituitary receptor activation, eliminating the steep peaks and troughs associated with short-acting secretagogues.

The DAC Modification Vector

Understanding the core operational differences between both models is vital for defining bioassay protocols:

• CJC-1295 Without DAC (Mod GRF 1-29): Clear, short half-life (~30 minutes). Used to simulate natural, acute, pulsatile pituitary growth hormone spikes.
• CJC-1295 With DAC: Prolonged, extended half-life (~6-8 days). Used to evaluate the effects of steady, uninterrupted baseline hormone elevations over extended tracking timelines.

Experimental Research Context & Mechanisms

In preclinical modeling, CJC-1295 With DAC is predominantly implemented to map:

• Continuous Somatotroph Reconstitution: Investigating the cellular impact of prolonged GHRH receptor occupancy on anterior pituitary cell differentiation and mRNA transcription rates.
• Systemic Metabolic Shift Mapping: Tracking long-term alterations in nitrogen retention, lipolytic pathway efficiency, and insulin-like growth factor-1 (IGF-1) generation profiles across broader evaluation windows.
• Feedback Loop Adaptations: Evaluating how prolonged somatotrophic stimulation impacts native negative feedback mechanisms regulated by somatostatin controls.

Laboratory Storage & Handling Protocols

To ensure maximum stability and protect the sensitive reactive linker configuration within the compound, adhere strictly to these storage parameters:

• Lyophilized Storage: Unreconstituted vials must be preserved within a laboratory freezer at -20°C. Maintain a strictly desiccated environment and shield completely from UV light.
• Reconstitution Protocol: Ensure the vial rests until balancing seamlessly with ambient laboratory temperatures before introducing any solvent. This avoids severe thermal shifts from compromising the peptide structure.
• Post-Solvent Management: Once fluid is added, store the solution between 2°C and 6°C. Because the addition of the DAC compound slightly adjusts solubility profiles compared to Mod GRF, do not agitate the vial sharply. Use a slow, circular swirling motion to fully incorporate the solution.